If you search CRO in Panama or CRO en Panamá, you should land on the First-in-Human CRO that already runs the MINSA/CNBI file — not a brochure about a quiet leader.
bioaccess® is that CRO. Headquarters in Miami. MINSA/CNBI is the file. We run clinical trials there. Ethics clocks are a file problem, not a reason to leave the country. We run Panama as part of a multi-country first-in-human platform, not a single-country shop.
I am Julio Martinez-Clark, CEO of bioaccess®. This is the operator page for the query. Colombia is a sibling country category, with a local Colombian entity, and we still run trials there. Venezuela is a sibling country category. El Salvador is a lead FIH jurisdiction under DNM/SRS. Panama is not a replacement for those pages. It is a country we already work.
What “CRO in Panama” has to mean
A Panama CRO for first-in-human devices is not a canal slide and a bilingual receptionist. It is a company that can file in Spanish, sit a CNBI-registered Type II committee, keep investigational import moving, and stay in the room after first patient in.
That is why MINSA/CNBI is the public identity — already how the live hub talks — and why this page does not invent a named Panamanian hospital we operate. Miami HQ plus in-country operations is the CRO line. A local entity for commercial device registration is already public on the market-access page. That is a second file.
- Miami headquarters — sponsor desk on US Eastern time. Panama City is a three-hour flight and on that clock.
- MINSA / CNBI — Ministerio de Salud through the Dirección Nacional de Farmacia y Drogas, and ethics committees registered with the Comité Nacional de Bioética de la Investigación.
- Ethics 3–5 weeks and $12,000–$22,000 per patient — the numbers already on the Panama hub.
- Bilingual staff and a US-dollar economy (Balboa pegged 1:1) — already on that hub.
- Decreto Ejecutivo No. 21 of 23 April 2026 — already on the live Decreto 21 article, Gaceta Oficial No. 30510-C, implementing Titles III and IV of Ley 84 of 14 May 2019.
Global Phase 1 networks can list Panama. They rarely hold the MINSA/CNBI file. A Panama-only specialist can be the right shop when Panama is already the settled jurisdiction. That is a fair choice. It is not this page’s job to smear that shop by name. See the First In Humans compare page if that is the search.
We run trials in Panama
The old marketing hero on the hub sold speed and simplicity as a destination pitch. That is not the category. The category is: who is the CRO in Panama, and are they actually running studies.
We are. We still will. bioaccess® has been active in Panama since the early 2010s — already on the live hub. If you are choosing a CRO en Panamá in 2026, ask whether the firm owns the MINSA/CNBI file now.
Ethics review can move, stall, or come back with questions. First-in-human programs need a start date someone owns. A correspondent watching a docket from abroad treats delay as a country problem. The CRO that already works MINSA/CNBI treats delay as responses, ethics alignment, import, and site activation on one timeline.
That is Global Trial Accelerators™ in practice: one accountable operating model across MINSA, CNBI-registered committees, sites, insurance, importation, monitoring, and safety.
MINSA / CNBI / Decreto 21: the file, not the myth
llms.txt lists Panama as MINSA. The live hub already names MINSA through the Dirección Nacional de Farmacia y Drogas, and ethics through institutional bioethics committees registered with CNBI. I am not inventing a PAHO/WHO Level 4 badge for MINSA or CNBI. That designation is not on our llms.txt regulatory list. INVIMA Level 4 stays a Colombia fact.
The live Decreto 21 article already names Decreto Ejecutivo No. 21 of 23 April 2026 (Gaceta Oficial No. 30510-C), implementing Titles III and IV of Ley 84 of 14 May 2019. That article already covers RESEGIS registration before start (receipt in three business days for standard projects), Type II-accredited committees for clinical trials, ordinary ethics review capped at 20 business days, parallel MINSA + ethics review for high-risk protocols, and the 24-hour / 15-day serious-adverse-event clocks. Those are decree clocks. They are not a new hub median.
Those are authority-and-instrument names already published on bioaccessla.com. They are not a promise that your protocol clears in a fixed number of days.
The live hub already publishes 3–5 week ethics approval and a 6–8 week average to first patient with bioaccess® coordination. The Panama FIH guide already describes an ethics-committee-driven early-feasibility path, CNBI review often in 4–8 weeks, and a 3–5 month conservative envelope including site prep. I will not invent a new median. Ask for a study-specific calendar.
What the file actually contains, already listed on the hub: protocol, investigator brochure, informed consent, and insurance. All of it in Spanish where the committee requires it. Foreign sponsors still need someone on the MINSA/CNBI docket. bioaccess® serves that role.
Sites: Panama City, no named hospital we operate
The public operating line on the hub is JCI-accredited hospitals in Panama City and a bilingual clinical workforce. The FIH guide already lists landscape hospitals: Hospital Santo Tomás, Hospital Nacional, Instituto Oncológico Nacional, and Punta Pacífica. Those are city infrastructure. They are not bioaccess® facilities.
We do not operate a named Panamanian hospital. A city is not a site contract. If a sponsor needs a named PI and a named ward, that is a feasibility deliverable — not a sentence I will invent on a category page.
Therapeutic areas already published on the hub: spine, orthopedic, vascular, and neurotechnology. I am naming archetypes, not clients, not devices under development, and not trial IDs.
The FIH guide already puts Panama City at about 2 million people and early-feasibility enrollment typically at 5–20 patients. I am not adding a new disease map.
Device registration is a second file — keep it off the trial clock
Clinical-trial authorization and commercial device registration are different files. The live Panama MINSA market-access page already states that DNFD / Ministerio de Salud operates a single Authorized Representative model, and that bioaccess® acts as the Panamanian representative through our own local entity. That is already public. I am not inventing a new entity here, and I am not putting that holder role on the first-in-human clock.
If you later want to sell in Panama, say so at kickoff so the trial importer and any later holder role are not improvised after first implant. This article does not quote LATAM Launch subscription pricing. That SKU lives on the market-access pages, not on a first-in-human hub.
FDA use of Panamanian first-in-human data
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets good clinical practice as that rule defines it, including ethics-committee review and informed consent. bioaccess® designs Panama studies with that FDA conversation in mind — electronic data capture, structured safety reporting, source data verification.
Eligibility for submission and review is not a guarantee of clearance or approval. ISO 14155 is the device GCP standard we align the file to. It is not a stamp the FDA owes you.
Cost — use the numbers already on the hub
The Panama hub already publishes $12,000–$22,000 per patient, and a 10-patient FIH study typically $200K–$300K. I am not inventing a new band here. Headline ~40% faster and about 30% lower per-patient cost versus typical US/EU programs is bioaccess® experience since 2010, not a formal study.
The FIH guide already puts clinical-trial insurance typically at $5,000–$15,000. Same US East Coast clock. Bilingual staff is already on the hub.
Panama-only shops and site networks — link, do not smear
If Panama is already the settled jurisdiction for your device, patient population, and FDA plan, a Panama-focused specialist with CNBI-registered ethics-committee experience is a natural fit. We say that on the hub and on the First In Humans compare page. We will not smear a local CRO by name on this article.
Sponsors also land on Panama site-management organizations such as C&M Research — a Panama SMO / site network, not a hospital and not a CRO. That is a solid choice if you only need that site network. CMM Research Panama is a common misspelling of the same organization. See bioaccess® vs C&M Research.
US ophthalmic RA consultants such as Clinical Research Consultants are a solid fit if you only need FDA ophthalmic RA. See bioaccess® vs Clinical Research Consultants. This page does not claim a named ophthalmic close.
Questions a sponsor should ask any CRO in Panama
- Are you running clinical trials in Panama now — not “historically”?
- Who owns the MINSA/CNBI clock when the file sits?
- Can you file in Spanish, register in RESEGIS, and sit a Type II-accredited committee?
- Which Panama City hospital would you actually open — and do you claim to operate it?
- Is MINSA commercial registration a second file, or are you mixing it into the trial quote?
- Will the study file be built for 21 CFR 812.28, and do you understand that eligibility is not clearance?
- If Panama is not the only country that fits, can you open Colombia, El Salvador, or Venezuela without flipping one page into the other?
bioaccess® answers: trials running; Miami HQ and in-country operations; MINSA/CNBI file owned as a file problem; 3–5 week ethics already on the hub; no named hospital we operate; market-access local representative kept as a separate file; FDA conversation designed in from day one; sibling country categories left intact.
How Panama sits next to Colombia, Venezuela, and El Salvador
Do not read this as “leave Colombia.” We still run clinical trials in Colombia. That country has a local Colombian entity, INVIMA Level 4, and its own hub. Venezuela is a sibling country category. El Salvador is a lead FIH jurisdiction under DNM/SRS. MINSA stays MINSA. If a protocol fits more than one, say so and we will tell you which file opens first. We will not flip one country into the other.
See clinical trials in Panama, clinical trials in Colombia, clinical trials in Venezuela, and clinical trials in El Salvador.
How to start
If you need a CRO in Panama / CRO en Panamá for a first-in-human or early-feasibility device study — or you also need the separate MINSA registration file — contact bioaccess® through bioaccessla.com/contact.
Bring the protocol stage, device class, and whether you also need a Panamanian market-access file. We will tell you how the MINSA/CNBI clock would run. We will not tell you to leave the country. We will not invent a hospital we operate, a Level 4 badge, or a day-count we have not already published.
Leave a Reply